Lenvima gets the FDA’s nod for differentiated thyroid cancer
Posted on: 13/02/2015 - 17:23
The Food and Drug Administration has approved the kinase inhibitor lenvatinib (Lenvima) for the treatment of differentiated thyroid cancer, the agency... More »
Field of Interest: Oncology
Type: News Item